This week, 12 Health Care Equipment & Supplies stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Zimmer Biomet Holdings, Inc. (ZBH) declines this week from a B to a D. For more information, get Portfolio Grader’s complete analysis of ZBH stock.
Orthofix International NV (OFIX) experiences a ratings drop this week, going from last week’s C to a D. Orthofix International NV is a global medical device company offering a line of surgical and non-surgical products mainly in the spine, orthopedics, sports medicine and vascular market sectors. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of OFIX stock.
Smith & Nephew PLC Sponsored ADR’s (SNN) rating weakens this week, dropping to a F versus last week’s D. Smith & Nephew PLC Sponsored ADR develops, manufactures, markets and sells of medical devices in the sectors of orthopaedics, endoscopy and advanced wound management. For more information, get Portfolio Grader’s complete analysis of SNN stock.
This is a rough week for Wright Medical Group NV (WMGI). The company’s rating falls to D from the previous week’s B. Wright Medical Group NV is a global orthopedic medical device company specializing in the design, manufacture and marketing of devices and biologic products for extremity, hip, and knee repair and reconstruction. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of WMGI stock.
Quidel Corporation (QDEL) earns a D this week, moving down from last week’s grade of C. Quidel Corporation discovers, develops, manufactures, and markets rapid diagnostic products for point-of-care detection of human medical conditions and illnesses. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of QDEL stock.
This week, Globus Medical, Inc. Class A (GMED) drops from a C to a D rating. Globus Medical, Inc. Class A focuses on the design, development, and commercialization of products that promote healing in patients with spine disorders. For more information, get Portfolio Grader’s complete analysis of GMED stock.
Invuity Inc (IVTY) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of IVTY stock.
Slipping from a C to a D rating, InVivo Therapeutics Corporation (NVIV) takes a hit this week. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of NVIV stock.
This week, Quotient Ltd.’s (QTNT) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in earnings revisions, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of QTNT stock.
Cesca Therapeutics Inc. (KOOL) is having a tough week. The company’s rating falls from a D to a F. Cesca Therapeutics Inc. designs, manufactures and markets automated and semi-automated devices and single-use processing disposables that enable hospitals and blood banks to manufacture a therapeutic dose of stem cells. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of KOOL stock.
Tandem Diabetes Care, Inc. (TNDM) slips from a D to a F this week. The company also gets F’s in sales growth, earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TNDM stock.
Slipping from a D to a F rating, NeuroMetrix, Inc. (NURO) takes a hit this week. NeuroMetrix, Inc. is a medical device company that designs, develops and sells proprietary products used to diagnose neuropathies. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NURO stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
